Transcatheter mitral valve repair (TMVr) has been approved, in the United States, for the treatment of degenerative mitral valve regurgitation (MR) in certain high surgical risk or inoperable patients. In a recent study by Jabs et al., the in-hospital outcomes (at 12 months) of pre-existing atrial fibrillation (Afib) did not differ considerably from those with sinus rhythm in regard to either major adverse cardiac and cerebrovascular event (MACCE) rates or clinical improvements [1]. However, it should be noted that Afib is a frequently encountered adverse outcome in the TMVr procedure [1] and is, in general, a marker for advanced heart failure [2].
